Quick Answer
Enliven Therapeutics, Inc. reported R&D Expense of $85.86 million for fiscal year 2025.
Enliven Therapeutics, Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $85.86M | +6.3% |
| 2024 | $80.78M | +25.1% |
| 2023 | $64.57M | +108.2% |
| 2022 | $31.02M | -19.3% |
| 2021 | $38.44M | +19.6% |
| 2020 | $32.15M | +69.2% |
| 2019 | $19.01M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $18.23M | -14.3% | -15.2% |
| June 30, 2025 | $21.49M | +14.2% | -13.7% |
| March 31, 2025 | $24.89M | +24.7% | +17.1% |
| September 30, 2024 | $21.26M | +8.4% | +12.9% |
| June 30, 2024 | $18.83M | +24.0% | -5.7% |
| March 31, 2024 | $19.97M | +68.1% | +1.9% |
| September 30, 2023 | $19.61M | +150.4% | +29.1% |
| June 30, 2023 | $15.18M | +91.3% | +27.8% |
- Enliven Therapeutics, Inc. showed an increase of +6.3% in R&D Expense compared to the prior fiscal year.
- Over the 2019–2025 period, Enliven Therapeutics, Inc.’s r&d expense has grown by 351.7% (from $19.01 million to $85.86 million).
- The most recent figure is from Enliven Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 3, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: